Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials
Chemotherapy and Targeted Therapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials
复制标题
DOI：
10.1159/000365781
复制
发表时间：
2014-01-01
期刊：
影响因子：
3.3
通讯作者：
Schmid, Roland M.
中科院分区：
文献类型：
--
作者：
Eckel, Florian;Schmid, Roland M.
背景：在胆道癌中，吉西他滨铂（GP）双联姑息化疗是目前的标准治疗。这项研究的目的是分析最近的试验，即使是那些小的和非随机的，并确定上级新的方案。方法：分析2000年1月至2014年1月期间以英文发表的试验，以及2010年至2013年的ASCO摘要。结果：共分析了161项试验，包括6，337例患者。标准治疗GP（无氟嘧啶、氟或其他药物）的汇总结果如下：中位缓解率（RR）、肿瘤控制率（TCR）、肿瘤进展时间（TIP）和总生存期（OS）分别为25.9%和63.5%，5.3和9.5个月。GFP三联方案和G为基础的化疗加靶向治疗在肿瘤控制（TCR、TIP）和OS方面均显著上级GP方案，但RR无差异。结论：GFP三联疗法以及基于G的化疗与（主要是EGFR）靶向治疗在肿瘤控制和生存方面是最有效的。(C)2014年S. Karger AG，巴塞尔
Background: In biliary tract cancer, gemcitabine platinum (GP) doublet palliative chemotherapy is the current standard treatment. The aim of this study was to analyze recent trials, even those small and nonrandomized, and identify superior new regimens. Methods: Trials published in English between January 2000 and January 2014 were analyzed, as well as ASCO abstracts from 2010 to 2013. Results: In total, 161 trials comprising 6,337 patients were analyzed. The pooled results of standard therapy GP (no fluoropyrimidine, F, or other drug) were as follows: the median response rate (RR), tumor control rate (TCR), time to tumor progression (TIP) and overall survival (OS) were 25.9 and 63.5%, and 5.3 and 9.5 months, respectively. GFP triplets as well as G-based chemotherapy plus targeted therapy were significantly superior to GP concerning tumor control (TCR, TIP) and OS, with no difference in RR. Conclusion:Triplet combinations of GFP as well as G-based chemotherapy with (predominantly EGFR) targeted therapy are most effective concerning tumor control and survival. (C) 2014 S. Karger AG, Basel